Literature DB >> 14999522

Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.

Yasuhiko Ogura1, Akinori Gonsho, Jong-Chol Cyong, Hajime Orimo.   

Abstract

Because of its chemical structure, risedronate was thought to form a complex with divalent cations, e.g., Ca(2+), and to be likely to show changes in the efficiency of absorbance from the gastrointestinal tract according to the presence of food. Therefore, we conducted a crossover study using healthy Japanese adults to examine the effects of food intake on absorption after the oral administration of risedronate and to choose the best timing of regimen for risedronate. Using single doses of 5 mg risedronate, the following four dose times were investigated: (a) in the morning under a fasting condition without breakfast; (b) 30 min before breakfast; (c) 30 min after breakfast; and (d) 3 h after breakfast. The results showed that the C(max) and AUC(0-24) of the plasma risedronate concentrations and its cumulative urinary excretions decreased in the following order: fasting without breakfast >>30 min before breakfast >>3 h after breakfast >>30 min after breakfast. In other words, it was demonstrated that the absorption of risedronate decreases due to the effects of food. Several adverse events, whose causality with risedronate was unknown or possibly related, were observed, including headaches, diarrhea, increased CK-BB, and an increased urinary Beta(2)-microglobulin excretion rate, but none of these events was clinically significant, and none differed in frequency or severity from the events after a single oral administration. In consideration of the optimal practical timings required to administer risedronate for Japanese patients, therefore, it was found that ingesting the drug immediately after waking up in the morning, when the stomach is empty, was optimal, and that it was necessary to refrain from eating and drinking for at least 30 min after drug ingestion. Therefore, we determined that the optimal time for risedronate to be administered in Japanese patients is 30 min before breakfast.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999522     DOI: 10.1007/s00774-003-0459-x

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  10 in total

1.  Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.

Authors:  Satoshi Soen; Hideaki Kishimoto; Hiroshi Hagino; Teruki Sone; Hiroaki Ohishi; Tsukasa Fujimoto; Emma Sasaki; Sakae Tanaka; Toshitsugu Sugimoto
Journal:  J Bone Miner Metab       Date:  2019-08-16       Impact factor: 2.626

Review 2.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

3.  Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells.

Authors:  Bo-Bae Kim; Youngkyung Ko; Jun-Beom Park
Journal:  Biomed Rep       Date:  2015-09-28

4.  Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.

Authors:  M R McClung; P D Miller; J P Brown; J Zanchetta; M A Bolognese; C L Benhamou; A Balske; D E Burgio; J Sarley; L K McCullough; R R Recker
Journal:  Osteoporos Int       Date:  2011-09-27       Impact factor: 4.507

5.  Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation.

Authors:  Plamen Kinov; Mihail Boyanov
Journal:  Int J Womens Health       Date:  2012-04-12

6.  Drug-related problems and medication reviews among old people with dementia.

Authors:  Bettina Pfister; Jeanette Jonsson; Maria Gustafsson
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-27       Impact factor: 2.483

7.  An open-label randomized study of the relative absorption of gastro-resistant risedronate taken fasted or with food versus immediate-release risedronate.

Authors:  Diane Kleinermans; Andrew Joyson; Heather Wray
Journal:  Pharmacol Res Perspect       Date:  2022-06

8.  The Effects of Various Food Products on Bisphosphonate's Availability.

Authors:  Monika Zielińska; Grzegorz Garbacz; Jaroslaw Sczodrok; Adam Voelkel
Journal:  Pharmaceutics       Date:  2022-03-27       Impact factor: 6.525

Review 9.  Optimal Dosing Regimen of Osteoporosis Drugs in Relation to Food Intake as the Key for the Enhancement of the Treatment Effectiveness-A Concise Literature Review.

Authors:  Agnieszka Wiesner; Mariusz Szuta; Agnieszka Galanty; Paweł Paśko
Journal:  Foods       Date:  2021-03-29

10.  Early tissue responses to zoledronate, locally delivered by bone screw, into a compromised cancellous bone site: a pilot study.

Authors:  Joerg Arnoldi; Antoine Alves; Philip Procter
Journal:  BMC Musculoskelet Disord       Date:  2014-03-23       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.